INTRODUCTION
Body weight change in patients with rheumatoid arthritis (RA) is a complex issue. On one hand, active disease could lead to weight loss and frank wasting, termed rheumatoid cachexia, which correlates with the intensity of systemic infl ammation. [1] On the other hand, some studies showed that a higher body mass index (BMI) is associated with less severe radiographic joint damage in the early phases of the disease. [2] Even, some evidence showed that all-cause mortality and cardiovascular-related mortality rates decrease with increasing BMI in RA patients. [3, 4] The subject becomes more complex when considering the adipose tissue as an active site that, by releasing adipocytokines, has some immunological eff ects. [5] Therefore, it seems to be a bidirectional relationship between body weight change and disease activity in patients with RA, which is not only aff ected by biological factors but also by patients' behaviors and life style. [6] The association of BMI and the amount of body fat with clinical course of RA is still a ma er of debate, and waist and hip circumferences and waist to hip ratio with treatment response, because they can provide more accurate information about the body fat distribution. [11] 
MATERIALS AND METHODS

Patients and se ings
This observational cohort study was conducted on patients with RA (16 to 80 year old) referred to the rheumatology clinic of a University Hospital in Isfahan (central Iran) in 2012. Consecutive patients who met the American College of Rheumatology (ACR) criteria for the classifi cation of RA [12] and had active disease based on the disease activity score using 28 joint counts (DAS28) >2.6 were included. [13] Those with previous toxicity to combination therapy with methotrexate plus hydroxychloroquine, and those with signifi cant change of BMI (≥10%) in the preceding three months were not included. Also, we excluded patients whose treatment contained DMARDs or drugs other than methotrexate plus hydroxychloroquine (e.g. sulfasalazine). Considering type-I error = 0.05, study power = 0.8, and expecting correlation between BMI and ΔDAS28 as at least 0.3, [9] the sample size was calculated as 106 cases. The ethics commi ee of the Isfahan University of Medical Sciences approved the study and informed consent was obtained from all patients.
Assessments
An internist interviewed with all patients and gathered demographic data (age, gender) and clinical data (disease duration, previous therapies) from patients' history and documents. Height, weight, and waist and hip circumferences were measured by an educated nurse. Body mass index (calculated as weight in kilograms divided by the square of height in meters) was categorized into underweight (<18.5 kg/m . [14] Patients were examined by a single rheumatologist who evaluated the number of swollen/tender joints, patient's global activity (general health) on a visual analog scale (VAS, 0 to 100), and disease functional class based on the American College of Rheumatology 1991 revised criteria. [15] All patients were referred to a reference laboratory for measurement of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Finally, DAS28 was calculated based on the formula of DAS28-ESR; 0.56 × √(TJC28) + 0.28 × √(SJC28) + 0.70 × lognat (ESR) + 0.014 × VAS, and classifi ed as in remission (<2.6), low (≥2.6 to <3.2), moderate (≥3.2 to ≤5.1), and high (>5.1) disease activity.
Treatment strategy
Most of the patients have been under treatment with methotrexate monotherapy or combination therapy with methotrexate plus hydroxychloroquine when they were evaluated for entering to our study. Considering response to previous therapies, the clinician started combination therapy (or increased drugs' dose) with methotrexate (7.5 to 10 mg/week) plus hydroxychloroquine (200 to 400 mg/day) and prednisolone (2.5 to 10 mg/day) based on the clinical course. Dosage of treatment and change of the treatment for patients was registered in data gathering form. Patients were followed for 24 weeks and DAS28 was calculated with the same rheumatologist again every 12 weeks. A decrease of >1.2 score in DAS28 was defi ned as response. [16] Statistical analysis Data were analyzed using the SPSS so ware for windows version 16 
RESULTS
Demographic data
From a total of 140 patients investigated during the study period, 19 patients were under treatment with DMARDs or drugs other than methotrexate plus hydroxychloroquine including sulfasalazine, tacrolimus, and cyclosporine. Also, 15 patients were lost to follow or had missing data. These patients were excluded from our analyses. Finally, 106 patients were included to the analyses and completely studied; (87.7% female) with mean age of 48.5 ± 13.8 years and mean disease duration of 4.4 years (SE = 0.48). Demographic data and clinical characteristics of all participants are presented in [ Table 1 ].
Factors associated with baseline disease activity and treatment response
Including all patients, there was a negative correlation between BMI and baseline DAS28 (r = −0.217, P = 0.026). DAS28 score was decreased from 4.5 ± 1.6 to 3.3 ± 1.5 a er 12 weeks of treatment (P = 0.005), and then was decreased to 2.9 ± 1.4 a er 24 weeks from starting the treatment (P < 0.001). The association between BMI and ΔDAS28 a er therapy was weak and not signifi cant (r = −0.132, P = 0.177). Regarding other anthropometric measures, there was no association of waist circumference or waist to hip ratio with baseline disease activity or with ΔDAS28 a er therapy [ Table 2 ].
With regards to DAS28 components, BMI was associated with baseline VAS score (r = −0.198, P = 0.040). Also, BMI (r = −0.301, P = 0.001) and waist circumference (r = −0.185, P = 0.020) were associated with the baseline number of swollen joint [ Table 2 ]. Regarding changes in DAS28 components a er therapy, there was only a week association between BMI and changes in ESR (r = −0.196, P = 0.043).
Defi ning response as a decrease of > 1.2 score in DAS28, comparison of responders and non-responders is presented in [ Table 3 ]. Responders were not different from nonresponders in terms of age, gender, disease duration, and anthropometric data. Although there was a trend for nonresponders to be more obese (41.3% vs. 25%, P = 0.184) and having higher BMI (28.9 ± 5.5 vs. 27.6 ± 4.0, P = 0.179) than responders, this diff erences were not statistically signifi cant.
Separate analysis of patients with disease duration of ≤2 years and >2 years
We categorized the patients to those with disease duration of ≤2 years indicating early disease and those with disease duration of >2 years. In those with early disease stage, analysis showed a signifi cant and strong association of BMI (r = -0.415, P = 0.005) and waist circumference (r = -0.296, P = 0.05) with baseline DAS28. BMI was also associated with the number of swollen joints (r = -0.415, P = 0.005) and tender joints (r = -0.338, P = 0.025), and with VAS score (patient's global activity) (r = -0.447, P = 0.002). In this group of patients, BMI (r = -0.337, P = 0.025) and waist circumference (r = -0.315, P = 0.038) were also correlated with ΔDAS28 a er therapy [ Table 4 ]. Also, responders had higher BMI (31.0 ± 5.5 vs. 27.1 ± 4.2) and greater waist circumference (95.8 ± 11.5 vs. 87.7 ± 11.6), [ Table 5 ]. None of the aforementioned associations or diff erences was present in patients with disease duration of >2 years.
Considering the difference between responders and non-responders in baseline DAS28 and also considering correlation between BMI and baseline DAS28, ANCOVA was applied to correct for the baseline DAS28. This analysis showed no infl uence of BMI on ΔDAS28 (F = 1.523, P = 0.223). Also, a linear regression analysis controlling for age, gender, disease duration, baseline DAS28, and methotrexate, hydroxychloroquine, and prednisolone total received dose showed no association between BMI and the amount of change in DAS28 (β = 0.019, 95% CI: −0.058 to 0.073), but there was a signifi cant association between baseline DAS28 with ΔDAS28 (β = 0.819, 95% CI: 0.714 to 1.145), [ Table 6 ]. By separate insertion of waist circumference and waist to hip ratio instead of BMI into the linear regression model, there was no association between these anthropometric measures and ΔDAS28 a er therapy. Also, separate linear regression analysis in 
DISCUSSION
The purpose of this study was to determine if BMI or other anthropometric measures including waist circumference and waist to hip ratio are associated with disease activity and clinical response to combination therapy with methotrexate and hydroxychloroquine in RA patients. With regard to the association between obesity and disease activity at the study entry, we found an inverse correlation of BMI with baseline disease activity. A er separating patients based on disease duration, this association was only present in patients with disease duration of ≤2 years. The association between waist circumference and baseline disease activity was also only present in these patients. These results were similar to some previous studies that have found a possible protective role for higher BMI in RA patients at early disease stages. [17, 18] Also, we found an association of BMI with clinically swollen and tender joint counts and also with patient's global activity in early disease stage. This fi nding was similar to radiologic studies in patients with early RA, of up to 3-year duration, indicating the protective role of higher BMI against joint damage. [2, [19] [20] [21] However, it must be noted that BMI was no longer associated with disease activity or separately with its components in patients with disease duration of more than 2 years. This finding indicates that the possible protective effects of obesity in early RA may be diminished later in the course of the disease. [17] Even, some studies have showed a direct association between obesity and disease activity in patients with long-time RA. [7, 22] In advanced RA, both underweight and obese states are associated with worse disease activity; an active disease lead to loss of lean body tissue and be er control of the disease is associated with weight gain. [23] Also, obesity increases the physical disability. [24] These fi ndings highlight the complex relationship between adiposity and obesity and clinical course in RA patients. Adipose tissue produces adipocytokines with various pro-infl ammatory and anti-infl ammatory eff ects, but the exact mechanisms behind the immune-modulatory eff ects of adipose tissue in RA patients are yet unexplored. [5, 17] With regard to the eff ects of obesity on treatment response, we found an inverse correlation of BMI and waist circumference with the amount of change in DAS28 a er therapy in patients at early disease stage. However, a er controlling baseline disease activity, these correlations were no longer existed, indicating a large confounding eff ect of the baseline disease activity. In contrast to these results, previous studies showed a high BMI associated with less well response to anti-TNFα agents even a er adjustment for the baseline disease activity. Klaasen et al. found that RA patients with a higher BMI have a more active disease at study entry and respond less well to infl iximab. [9] The study Data are presented as Pearson or Spearman correlation coeffi cients; * P < 0.05 and ** P < 0.001; ESR = Erythrocyte sedimentation rate; BMI = Body mass index; DAS28 = Disease activity score in 28 joints; VAS = General health on a visual analog scale by Gremese and colleagues in a larger sample of patients (n = 641) and longer treatment period (12 months) with anti-TNFα blockers (Adalimumab, Etanercept, and Infl iximab) found no association between BMI and disease activity at baseline, but be er response to infl iximab in those with lower BMI and lower disease activity at baseline. [10] In another recent study by Heimans and colleagues, [25] 508 patients were allocated to initial monotherapy with methotrexate or combination therapy of methotrexate with prednisone or infl iximab for 1 year. Authors found that higher BMI was associated with failure to achieve response (a DAS ≤2.4) on initial therapy with methotrexate. In this study, high BMI (≥25 kg/m 2 ) was also associated with failure on delayed combination therapy with infl iximab, and in the fi rst year a er starting the study, patients with a high BMI had higher DAS, worse functional ability, more tender joints and a higher VAS global health. But, high BMI in this study was not associated with more swollen joints or systemic infl ammation. [25] Diff erences between these fi ndings and ours may be related to diff erent patients' characteristics and diff erent treatments. Patients in the mentioned studies had longer disease duration. Also, our patients had signifi cantly higher BMI (28.2 kg/m 2 ) compared with the mentioned studies (24.9 and 26), while disease activity score was lower in our study (4.5 vs. 5.6 and 5.9). Anyway, the exact role of BMI in response to various treatments in patients with various disease stages is yet to be clarifi ed.
It has been suggested that the association of obesity with disease activity and response to treatment in RA patients may be due to high levels of proinfl ammatory cytokines produced by adipocytes. [5, 26] Waist circumferences and waist to hip ratio provide more accurate information about the body fat distribution. Hence, we evaluated these parameters to be er investigate if adipose tissue has a role in creating an infl ammatory and therapy-resistant state in RA patients. However, compared with BMI, we found smaller correlation coeffi cient of waist circumference and no association of waist to hip ratio with disease activity. In our study as well as in previous studies, BMI and waist circumference were associated with baseline swollen joint count, rather than infl ammatory markers. These fi ndings are not in favor of a mechanism involving adipose tissue-derived mediators of infl ammation. [9, 25] It should be considered that clinical synovitis might be less easy to assess in RA patients with obesity and it is possible that our study as well as others underestimated joint swelling, associated with a local infl ammation, in patients with a high BMI. [25] More investigations including advanced imaging and biomarker studies are needed to further elucidate the relation between BMI and disease activity as well as treatment response.
There are some limitations to our study. The association between obesity and treatment response in our study has been confounded by baseline disease activity. Indeed, a larger sample of patients was required for more precise evaluation of the role of obesity on various components of RA activity as well as in diff erent disease stages, and consideration of possible confounders. Moreover, our study period was six months which, compared to other studies, was not long enough. Although, in addition to BMI, we investigated waist circumference and waist to hip ratio which provide more accurate information about the body fat distribution, [11] these are not the most accurate measures, and also we did not evaluate adipocytokines, the hypothesized underlying mediators.
CONCLUSIONS
Our study results showed that obesity is associated with less severe disease activity in early stage of RA, but is not associated with response to combination therapy with methotrexate plus hydroxychloroquine in RA patients. However, due to our study limitations, these results should be considered with cautious. Further cohorts with larger sample size and longer follow-ups, and with more accurate investigation of body adipose composition and possible immunological mechanisms, are warranted in this regards.
